AI-Powered Chimeric Receptors to Overcome Therapeutic Resistance in Myeloma (A08*)

• Subject Area: Hematology, Oncology ; Immunology
• Term: since 2026
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 452881907

Development and validation of novel AI-designed chimeric receptors (AI-CRs) for engineered T-cell therapy to target resistance mechanisms in multiple myeloma. Multi-specific AI-CRs simultaneously targeting BCMA, TACI, and GPRC5D aim to overcome antigen escape and antigen downregulation, enhancing therapeutic durability. Combining innovative protein design with precise genomic integration will improve engineered T-cell persistence and efficacy, enabling robust and long-lasting therapeutic responses for myeloma patients.

• DFG Programme: CRC/Transregios
• Subproject of: TRR 338: LETSIMMUN - Lymphocyte Engineering for Therapeutic Synthetic Immunity
• Applicant Institution: Technische Universität München (TUM)
• Project Head: Dr. Andrea Schmidts